Company: EUDAW
Filing Date: 2025-04-29
Form Type: 20-F
Source: 0001641172-25-006627
Chunk: 16

Company: EUDA Health Holdings Ltd
Filing Date: 2025-04-29
Form: 20-F
Item: Item 3
Chunk 16
---
 towards creating its own payment ecosystem
through the introduction of its own digital currency in the future and that will help the Company in having a more standardized system
and help reduce FX risks. The Company also has a certain level of natural hedge in the countries in which it operates as its revenues
and major costs in individual markets are both denominated in the same currency.

EUDA’s
growth depends on the success of the Company’s strategic relationships with third parties and partners.

EUDA
anticipates that it will continue to depend on relationships with third parties, including partner organizations and technology and healthcare
providers to grow the Company’s business. As of the date of this report, CK Health has signed two agency contracts giving it the
exclusive rights to distribute certain collagens of “ YOROYAL” brand in Malaysia, Vietnam and Indonesia, and certain bioenergy
cabins in Malaysia. In April 2025, CK Health entered into a collaboration agreement with Key Lock Health Management Co., Ltd. (“ Key Lock”), an authorized distributor of Guangdong Cell Biotech
Co. Ltd. (“ Guangdong Cell Biotech”), ”), a prominent player in stem cell therapies and regenerative medicine, that develops
autologous cell treatments and tailored medicines for various disorders. Key Lock is responsible for promoting and selling Guangdong Cell
Biotech’s stem cell therapy packages, managing sales, market development and customer support. Pursuant to the collaboration agreement
with Key Lock, CK Health will purchase from Key Lock certain stem cell therapy services offered by Guangdong Cell Biotech at certain pre-determined
prices and market and sell these services in Singapore and Malaysia; and Key Lock will use its commercial endeavours to ensure proper
stem cell therapy services received by EUDA customers at one of Guangdong Cell Biotech’s treatment centers in China. CK Health does
not have the exclusive right to sell Guangdong Cell Biotech’s stem cell services in Singapore or Malaysia. This collaboration agreement
is terminable by either party with one month’s notice of termination. If Key Lock loses its rights to distribute services for Guangdong
Cell Biotech, it is very likely that EUDA will also lose its rights to distribute Guangdong Cell Biotech’s stem cell therapies in
Singapore and Malaysia. Identifying partners, and negotiating and documenting relationships with them, requires significant time and resources. The
Company’s competitors may be more effective in incentivizing such potential partners to favor their products or services over EUDA’s.
In addition, acquisitions of EUDA’s existing